New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma. The results from ...
Nov 12, 2015
0
10
Several new immunotherapeutic antibodies that inhibit checkpoint receptors on T cells to restimulate the immune system to target tumors have been approved to treat advanced stage lung cancer and melanoma; however, only 20 ...
Mar 31, 2016
0
11
Graft-versus-host-disease (GVHD) is the leading cause of non-relapse associated death in patients who receive stem cell transplants. In a new study published as the cover story in Science Translational Medicine, Moffitt Cancer ...
Jan 11, 2017
0
63
Melanoma is one of the most aggressive types of skin cancer, but recent advances in targeted therapies have improved the prognosis for many patients. Unfortunately, for some patients these positive outcomes are not long lasting, ...
Apr 15, 2019
0
3
Lymphoma is the most common blood cancer. The disease occurs when immune cells called lymphocytes multiply uncontrollably. Cancerous lymphocytes can travel throughout the body and form lymph node tumors. The body has two ...
Jan 5, 2017
0
1
Lung cancer is the leading cause of cancer death for men and women. It is also one of the most complex cancers, both at the molecular level and through its clinical behavior. Screening is paramount as it helps physicians ...
Aug 18, 2016
0
0
Cells in the surrounding tumor microenvironment have a significant impact on cancer growth, survival and responses to therapy. Cancer-associated fibroblasts in the tumor environment have typically been associated with tumor ...
Aug 16, 2022
0
143
Elderly cancer patients who are HIV-positive, particularly those with prostate and breast cancers, have worse outcomes compared to cancer patients in the same age range who do not have HIV. A Moffitt Cancer Center researcher, ...
Aug 1, 2019
0
1
Immunotherapies have improved outcomes of many patients with cancer, including melanoma. But these therapies work for only a subset of patients. Numerous studies are looking at improving responses, including research focusing ...
Jan 23, 2023
0
56
Kidney cancer accounts for only 4% of all cancers in the United States; however, its incidence has more than doubled since 1975, with the most common type being clear cell renal cell carcinoma. While outcomes of patients ...
Jul 8, 2022
0
60
